Urinary incontinence is the involuntary leakage of urine—meaning you leak urine even when you don’t want to. There are several types of urinary incontinence, but the most common are urge incontinence, stress incontinence, and overflow incontinence. Some people may even experience symptoms of more than one type, known as mixed incontinence.
This article focuses on urge incontinence, which happens when a person suddenly feels a strong, urgent need to urinate and cannot hold it in, often leading to accidental leakage. It’s closely linked to a condition called overactive bladder (OAB).
Although the overall number of men with incontinence is lower than that of women, urge incontinence is actually the most common type among men, seen in about 40% to 80% of cases.
Urge incontinence can have a major impact on a man’s quality of life. It may cause emotional stress, embarrassment, and even lead to avoiding everyday activities like going out or exercising. It can also affect personal relationships and lead to financial burdens if special products or treatments are needed. That’s why recognizing and treating it properly is so important.
Causes and Risk Factors
Urge incontinence in men is commonly linked to abnormalities in the function of the bladder’s detrusor muscle—the smooth muscle responsible for bladder contractions. The most frequent causes include:
Detrusor Overactivity: This involves involuntary contractions of the bladder muscle during the filling phase, which can lead to a sudden urge to urinate. It may arise from neurological conditions like Parkinson’s disease, spinal cord injury, or stroke, but can also occur without a known cause (idiopathic).
Poor Detrusor Compliance: In this case, the bladder fails to stretch properly, resulting in increased pressure, discomfort, and reduced storage capacity. It is often associated with pelvic radiation therapy or long-term catheter use.
Bladder Hypersensitivity: The bladder becomes overly sensitive, often due to irritation or inflammation of the bladder lining (urothelium). This may be related to infections or disruptions in the urinary microbiota, and it can contribute to urgency symptoms.
Other contributing factors include:
Benign Prostatic Hyperplasia (BPH): An enlarged prostate can disrupt normal urinary flow and bladder function, sometimes leading to urge incontinence.
Post-Prostate Surgery: Surgical procedures such as prostatectomy may alter bladder control and increase the risk of urgency and leakage.
Symptoms
Sudden and intense urge to urinate, followed by involuntary leakage.
Frequent urination, often more than 7 times per day.
Nocturia, or waking up at night multiple times to urinate.
Episodes of urgency-related leakage, which may occur even before reaching the bathroom.
Lifestyle Modifications:
First-line treatment for urge urinary incontinence (UUI) focuses on nonpharmacological strategies. Bladder training helps individuals increase the time between voids and reduce urgency episodes. Pelvic floor muscle exercises (Kegels) can strengthen the muscles that control urination, although some studies suggest limited effectiveness in women with UUI. Behavioral interventions—like urge-suppression techniques and educational support—have shown benefits, particularly in patients dissatisfied with medication. Dietary adjustments, including reducing caffeine and alcohol, may lessen bladder irritability and urgency. These strategies are especially important for elderly individuals, where detrusor overactivity and age-related brain changes contribute to UUI.
When to Consider Medications:
Pharmacological treatment is appropriate when lifestyle changes are insufficient or when symptom severity impacts quality of life. Antimuscarinic agents, such as tolterodine ER, have demonstrated efficacy in reducing urgency and improving patient-reported outcomes, especially when combined with behavioral interventions. Other emerging options include β3-agonists, botulinum toxin injections, percutaneous tibial nerve stimulation, and sacral nerve stimulation. These therapies offer additional choices for patients with refractory symptoms, allowing individualized treatment based on severity, tolerability, and preference.
For men with urge urinary incontinence (UUI), pharmacological treatment is typically considered after first-line behavioral therapies prove insufficient. The goal is to reduce detrusor overactivity, increase bladder capacity, and modulate sensory input to the bladder.
Antimuscarinic Agents
Mechanism of Action: Antimuscarinics inhibit muscarinic (M2 and M3) receptors in the bladder, suppressing involuntary contractions of the detrusor muscle and improving bladder storage.
Common Medications:
Clinical Considerations:
Despite their widespread use, antimuscarinic agents often lead to central (confusion, cognitive decline) and peripheral (dry mouth, constipation, urinary retention) side effects. These are especially concerning in older men and those with benign prostatic hyperplasia (BPH). Selective agents like darifenacin may be preferred to reduce cognitive risks. Regular monitoring is recommended, particularly in those on multiple medications or with comorbidities.
Beta-3 Adrenergic Agonists
Mechanism of Action: These agents, such as mirabegron and vibegron, activate beta-3 receptors on the detrusor muscle, promoting bladder relaxation and reducing urgency episodes.
Advantages:
Considerations:
Mirabegron may elevate blood pressure or cause headaches. As such, cardiovascular status should be assessed before initiation. Combining a beta-3 agonist with an antimuscarinic can enhance efficacy while mitigating side effects.
Combination Therapy
Combining an antimuscarinic (e.g., tolterodine) with an alpha-blocker (e.g., tamsulosin) is particularly beneficial for men with coexisting UUI and BPH. This dual approach targets both storage and voiding symptoms.
Benefits:
Risks:
Phosphodiesterase-5 Inhibitors (PDE5i)
Mechanism of Action: PDE5 inhibitors improve blood flow and may relax bladder muscles.
Example:
Side Effects: Headache, indigestion, and flushing are the most commonly reported adverse events.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Mechanism of Action: SNRIs such as duloxetine increase norepinephrine and serotonin levels, enhancing urethral sphincter tone.
Use in UUI:
Common Side Effects: Nausea, dry mouth, and fatigue. Caution is advised in patients with depression or those on other serotonergic medications.
Neuromodulation
Percutaneous Tibial Nerve Stimulation (PTNS) is a minimally invasive procedure that uses electrical impulses near the ankle to modulate bladder-related nerve signals.
Sacral Neuromodulation (SNM) involves an implanted device that stimulates sacral nerves to restore normal bladder control. It is a second-line treatment for UUI and works by inhibiting abnormal sensory signals in the spinal cord.
Botulinum Toxin Injections
Botulinum toxin A (BTX-A), injected directly into the detrusor muscle via cystoscopy, blocks acetylcholine release, causing temporary chemical denervation. This reduces involuntary bladder contractions, increases bladder capacity and compliance, and improves quality of life. Typically lasting 3–6 months, repeat injections are often necessary. Studies with onabotulinumtoxinA (100–150 units) show it is effective for idiopathic UUI and OAB, though urinary retention and UTIs are possible side effects.
Investigational Agents
New treatments being studied include imidafenacin (a Japanese antimuscarinic) and neurokinin-1 receptor antagonists, though neither outperforms current therapies. Mirabegron, a β3-adrenoceptor agonist, offers an oral alternative that reduces UI episodes and frequency, with better tolerability for older adults. These options offer hope for patients unresponsive to standard therapies.
Selecting the appropriate treatment for urge urinary incontinence requires an individualized approach. Patient-specific factors—such as age, comorbidities, cognitive function, preferences, and the type and severity of symptoms—must guide therapy choices. Differentiating between urge, stress, mixed incontinence, and overactive bladder is essential to avoid misdiagnosis.
Regular follow-up is crucial to assess treatment effectiveness, manage adverse effects, and adjust therapy as needed. Behavioral therapy, medication, and neuromodulation options must be tailored accordingly. Older adults with cognitive impairment may benefit from early neuromodulation, while younger individuals often respond well to conservative measures. A shared decision-making process ensures optimal outcomes and patient satisfaction.
Urge incontinence in men can be effectively managed through a combination of lifestyle changes, medications, and advanced therapies—each tailored to the individual’s health status, symptoms, and preferences. Accurate diagnosis and ongoing evaluation are key to successful outcomes.
If you or a loved one is managing incontinence, try QuickChange Wraps—an easy-to-use, mess-free solution designed for comfort and confidence.
For those seeking support, we invite you to purchase a 10 Count Trial Pack here or request a professional-use sample pack for healthcare institutions here.
Abrams, P., Kelleher, C., Staskin, D., Rechberger, T., Kay, R., Martina, R., Newgreen, D., Paireddy, A., van Maanen, R., & Ridder, A. (2015). Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). European Urology, 67(3), 577–588. https://doi.org/10.1016/j.eururo.2014.02.012
Anger, J. T., Weinberg, A., Suttorp, M. J., Litwin, M. S., & Shekelle, P. G. (2010). Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature. The Journal of Urology, 183(6), 2258–2264. https://doi.org/10.1016/j.juro.2010.02.009
Chapple, C. R., Cardozo, L., Nitti, V. W., Siddiqui, E., & Michel, M. C. (2014). Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourology and Urodynamics, 33(1), 17–30. https://doi.org/10.1002/nau.22505
Chen, H., Wang, F., Yu, Z., Zhang, Y., Liu, C., Dai, S., Chen, B., & Lv, J. (2017). Efficacy of daily low-dose tadalafil for treating overactive bladder: Results of a randomized, double-blind, placebo-controlled trial. Urology, 100, 59–64. https://doi.org/10.1016/j.urology.2016.11.008
Demaagd, G. A., & Davenport, T. C. (2012). Management of urinary incontinence. P & T, 37(6), 345–361H. PMC3411204
Frenkl, T. L., Zhu, H., Reiss, T., Seltzer, O., Rosenberg, E., & Green, S. (2010). A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. The Journal of Urology, 184(2), 616–622. https://doi.org/10.1016/j.juro.2010.03.147
Homma, Y., Yamaguchi, T., & Yamaguchi, O. (2008). A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology, 15(9), 809–815. https://doi.org/10.1111/j.1442-2042.2008.02104.x
Huang, Y. C., & Chang, K. V. (2023). Kegel exercises. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554556/ (PMID: 32310358)
Igawa, Y. (2000). Discussion: Functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder. Urology, 55(5A Suppl), 47–49; discussion 50. https://doi.org/10.1016/s0090-4295(99)00493-8
Mayo Clinic Staff. (n.d.). Bladder control problems: Lifestyle strategies ease problems. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/urinary-incontinence/in-depth/bladder-control-problems/art-20044220
Nandy, S., & Ranganathan, S. (2022). Urge incontinence. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK563172/
Nitti, V. W. (2001). The prevalence of urinary incontinence. Reviews in Urology, 3(Suppl 1), S2–S6. PMC1476070
Scarneciu, I., Lupu, S., Bratu, O. G., Teodorescu, A., Maxim, L. S., Brinza, A., Laculiceanu, A. G., Rotaru, R. M., Lupu, A. M., & Scarneciu, C. C. (2021). Overactive bladder: A review and update. Experimental and Therapeutic Medicine, 22(6), 1444. https://doi.org/10.3892/etm.2021.10879
Willis-Gray, M. G., Dieter, A. A., & Geller, E. J. (2016). Evaluation and management of overactive bladder: Strategies for optimizing care. Research and Reports in Urology, 8, 113–122. https://doi.org/10.2147/RRU.S93636
Wyman, J. F., Klutke, C., Burgio, K., Guan, Z., Sun, F., Berriman, S., & Bavendam, T. (2010). Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Canadian Journal of Urology, 17(4), 5283–5290.